This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TNFRSF10B / Tumor necrosis factor receptor superfamily member 10B · IHC design guide
Design Immunohistochemistry for TNFRSF10B
Plan TNFRSF10B paraffin IHC around cytoplasmic tissue staining (HPA tissue IHC) and membrane topology (UniProt). Start with the catalog antibody's 0.5–1 μg/mL IHC range (datasheet: A00410), compare high-staining adipocytes with low-staining glia (HPA tissue IHC), and score compartments separately.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TNFRSF10B Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasm observed (HPA tissue IHC); membrane topology (UniProt) | |
| Staining pattern | Ubiquitous cytoplasmic staining across tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A00410) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A00410) | |
| Caveat | Brain staining varies: Purkinje cells high, glia low (HPA tissue IHC) | |
| Regulation | HCMV UL141 blocks surface expression (UniProt) | |
| Isoform / epitope | 3 isoforms; check extracellular vs cytoplasmic epitope coverage (UniProt) |
Section 1
Recommended TNFRSF10B IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet A00410) is accompanied by published TNFRSF10B IHC methods for synovial tissue (PMC13607894) and lung autopsy sections (PMC10417228).
| Sample | Paraffin-embedded rat kidney tissue; fixative not specified (datasheet A00410) |
| Fixation | Image fixative and duration unreported (datasheet A00410); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A00410); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00410) |
| Primary antibody | Rabbit anti-TNFRSF10B, 0.5-1μg/ml (datasheet A00410) |
| Primary incubation | Overnight at 4 °C (datasheet A00410) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A00410) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TNFRSF10B-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: Ubiquitous cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A00410); the lung study used citrate pH 6.0 (PMC10417228).
Section 2
What Is the Expected TNFRSF10B Staining Pattern?
TNFRSF10B is a transmembrane receptor with an extracellular region and cytoplasmic tail (UniProt O14763 topology). In paraffin-section IHC, expect broadly distributed cytoplasmic staining, including adipocytes, glandular cells, respiratory epithelium, hematopoietic cells and endothelial cells in the tissues listed by HPA (HPA: tissue IHC). HPA rates the tissue staining Approved, with medium consistency between antibody staining and RNA expression (HPA: reliability).
| Cytoplasmic staining in adipocytes, glandular cells or bronchial respiratory epithelium. | This matches the reported high staining in adipose tissue, adrenal gland, appendix, breast and bronchus (HPA: tissue IHC). Score the identified cell population and intensity; do not require a sharp membrane rim, because HPA describes its tissue pattern as cytoplasmic (HPA: tissue IHC). |
| A clear nuclear-only pattern, without the expected cytoplasmic staining. | Treat this as a compartment mismatch requiring investigation: UniProt places TNFRSF10B in membranes, while HPA reports cytoplasmic tissue IHC staining (UniProt O14763 subcellular location; HPA: tissue IHC). Check the negative control and examine whether counterstain or detection precipitate is being mistaken for specific signal (general IHC practice). |
| Strong staining in an unexpected cell population, while the expected population is unstained. | Check cell identity before calling cross-reactivity. HPA describes ubiquitous expression and high staining in several distinct cell types, so staining outside one selected population is not automatically abnormal (HPA: tissue IHC). A pattern confined to an implausible population can reflect nonspecific antibody binding or endogenous detection activity (general IHC practice). |
| Even colour across cells and empty slide areas, obscuring cellular boundaries. | This is background rather than a readable TNFRSF10B pattern. The reported result is cellular cytoplasmic staining (HPA: tissue IHC). Review blocking, washes and chromogen development; use a negative control to assess antibody-independent colour (general IHC practice). |
| No signal in a sample expected to stain strongly. | First confirm the sampled cell type: HPA reports high staining in adipocytes, bone-marrow hematopoietic cells and several glandular populations, among others (HPA: tissue IHC). A blank run warrants review of section quality, retrieval, antibody incubation and detection controls (general IHC practice); it does not establish absent TNFRSF10B expression. |
💡Expected TNFRSF10B appearanceCall a result positive when identifiable cells show cytoplasmic staining, potentially with a membrane-associated component, at an intensity interpretable against controls; HPA reports high staining in specified adipocytes, glandular, respiratory epithelial, hematopoietic and endothelial populations (HPA: tissue IHC), while nuclear-only colour or uniform background warrants investigation (UniProt O14763 subcellular location; general IHC practice).
| Which compartment should guide scoring? | UniProt assigns TNFRSF10B to the membrane, with residues 56–210 extracellular, 211–231 transmembrane and 232–440 cytoplasmic (UniProt O14763 topology). HPA describes tissue IHC as ubiquitously cytoplasmic (HPA: tissue IHC). Record the observed compartment instead of treating membrane-only staining as a requirement. |
| How strong is the tissue-pattern evidence? | HPA calls the IHC evidence Approved and notes medium consistency with RNA expression; HPA023625 is listed as IHC Approved (HPA: reliability; HPA: antibodies). These labels support use of the reported pattern for comparison, but do not make every stained cell or specimen independently verified. |
| Can expression be inferred from a single tissue or brain region? | HPA reports high staining in cerebellar Purkinje cells and low staining in hippocampal and caudate glia (HPA: tissue IHC). UniProt states that TNFRSF10B is not detectable in brain (UniProt O14763 tissue specificity). Keep these source-specific observations distinct when selecting controls or interpreting brain sections. |
| Can isoforms or processing explain a changed stain? | UniProt lists three isoforms and a signal peptide at residues 1–55, with the mature chain spanning residues 56–440 (UniProt O14763 isoforms; processing). The supplied sources do not map the IHC antibody epitope, so they cannot establish which isoform an apparent pattern detects or predict an epitope-specific result. |
| What does the IF/ICC evidence show? | HPA summarizes the subcellular location as membrane, but provides no main location or cell-line ICC-IF images in this payload (HPA: subcellular ICC-IF). That summary offers a localization comparison, not an IF/ICC staining pattern or a validated IF/ICC procedure. |
| Situation | Likely cause | Next action |
|---|---|---|
| A high-staining reference population is blank. | The run may have failed at retrieval, antibody incubation or detection; absence of colour alone cannot identify the failed step (general IHC practice). | Check tissue morphology and run controls, then review the recorded retrieval, incubation and detection steps (general IHC practice). Compare with a documented high-staining population, such as HPA-listed adipocytes or glandular cells (HPA: tissue IHC). |
| Colour appears in the negative control. | Antibody-independent colour can arise from endogenous enzyme activity or detection reagents, depending on the chromogenic system (general IHC practice). | Identify the detection system, apply its appropriate endogenous-activity control or block, and repeat the negative control before scoring (general IHC practice). |
| The section has diffuse haze or precipitate. | Insufficient washes, concentrated reagents or excessive chromogen development can obscure cellular staining (general IHC practice). | Review washes, reagent preparation and development time; accept the result only when cell boundaries and negative areas remain readable (general IHC practice). |
| Staining appears nuclear-only. | The compartment disagrees with the membrane assignment and reported cytoplasmic tissue pattern (UniProt O14763 subcellular location; HPA: tissue IHC). | Recheck morphology, counterstain and negative control, then repeat with a suitable positive tissue control if the mismatch persists (general IHC practice). |
| An unexpected cell population stains strongly. | The population may be genuinely positive because HPA reports broad expression, or the signal may be nonspecific (HPA: tissue IHC; general IHC practice). | Identify the cells on the counterstained section and compare cellular localization, expected tissue pattern and negative control before assigning specificity (HPA: tissue IHC; general IHC practice). |
| Brain sections give conflicting results. | The supplied sources differ: HPA reports high staining in cerebellar Purkinje cells, whereas UniProt describes brain expression as not detectable (HPA: tissue IHC; UniProt O14763 tissue specificity). | Report the region and cell type alongside the staining result; interpret it against the relevant HPA image and run controls without treating either broad brain statement as a universal IHC control (HPA: tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing TNFRSF10B staining
A00410 · IHCIHC analysis of DR5 using anti-DR5 antibody (A00410). DR5 was detected in a paraffin-embedded section of rat kidney tissue. Heat mediated an
A00410 · IHCIHC analysis of DR5 using anti-DR5 antibody (A00410). DR5 was detected in a paraffin-embedded section of mouse intestine tissue. Heat mediat
A00410-2 · IHCImmunohistochemistry Validation of DR5 in Mouse kidney tissue Immunohistochemical analysis of paraffin-embedded mouse kidney tissue using an
A00410-2 · IHCImmunohistochemistry Validation of BIM in Human Colon Tumors (Devetzi et al., 2016) Protein analysis for DR5 by immunohistochemistry with an
A00410-2 · IFImmunofluorescence Validation of DR5 in Human HepG2 Cells Immunofluorescent analysis of 4% paraformaldehyde-fixed human HepG2 cells labeling
A00410-5 · IHCIHC analysis of DR5/TNFRSF10B using anti-DR5/TNFRSF10B antibody (A00410-5). DR5/TNFRSF10B was detected in a paraffin-embedded section of hum
A00410-5 · IHCIHC analysis of DR5/TNFRSF10B using anti-DR5/TNFRSF10B antibody (A00410-5). DR5/TNFRSF10B was detected in a paraffin-embedded section of hum
PA1842 · IHCAnti-DR5 antibody, PA1842, IHC(P) IHC(P): Human Lung Cancer Tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000120889-TNFRSF10B/tissue/cerebral+cortex#imid_6011016
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000120889-TNFRSF10B/tissue/colon#imid_6011534
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000120889-TNFRSF10B/tissue/liver#imid_6011535
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000120889-TNFRSF10B/tissue/kidney#imid_6011528
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TNFRSF10B IHC & IF
🧪Run adipose tissue first and assess staining in adipocytes (HPA: High in adipocytes). HPA detects TNFRSF10B in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and expect cells without specific staining on the positive slide to show only background rather than assigning an unverified negative cell type (HPA: no negative tissue rows).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: TNFRSF10B is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for TNFRSF10B; derive a cell-line control from the positive tissue's cell type (Adipocytes) and confirm it by RNA or western blot first.
Technical controls: Run secondary-only and matched rabbit IgG isotype controls alongside a TNFRSF10B knockout biological control (selected A00410 caption: rabbit primary antibody). Block endogenous peroxidase and check for endogenous biotin before using the caption’s biotin-based DAB detection, especially where blood or inflammatory cells are present (selected A00410 caption: biotinylated secondary, SABC and DAB).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected A00410 paraffin-section caption does not state the fixative (selected A00410 caption: fixative unreported). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required or that frozen sections or IF are easier (selected A00410 caption: EDTA retrieval; HPA: no ICC-IF image cell lines). In adipose sections, lipid removal during paraffin processing can leave thin adipocyte rims and tissue gaps, so assess staining against intact cell outlines rather than empty spaces (standard paraffin IHC practice).
HPA tissue IHC evidence for TNFRSF10B
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: TNFRSF10B is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced TNFRSF10B IHC Tips
Troubleshoot TNFRSF10B staining in paraffin sections by checking retrieval, compartment, cell type, detection background, and scoring before interpreting chromogenic signal.
How should I retrieve TNFRSF10B in paraffin sections when staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A00410). The selected rat kidney image used that retrieval before incubation with 1 μg/ml antibody overnight at 4°C (datasheet A00410). If staining is weak, compare retrieval duration or another buffer on adjacent sections while keeping antibody concentration and detection conditions fixed (standard IHC practice). Include a section processed with the documented method in each comparison, so a change in signal can be attributed to retrieval (standard IHC practice). Judge improvement by cell-associated staining and background together, rather than DAB intensity alone (standard IHC practice).
Can I infer which fixative best preserves the TNFRSF10B epitope?
No target-specific fixation sensitivity is established: the selected image describes a paraffin section but does not report its fixative (datasheet A00410). Record the fixative and processing history for each specimen, and compare matched sections when those conditions vary (standard IHC practice). Apply the documented EDTA pH 8.0 retrieval and 1 μg/ml primary antibody conditions consistently during that comparison (datasheet A00410). If a specimen stains weakly, assess morphology and an appropriate control before assigning the result to fixation (standard IHC practice). The tissue staining profile and membrane topology do not supply evidence for a preferred fixative or fixation time (HPA tissue IHC; UniProt O14763 topology).
Should TNFRSF10B stain the membrane, cytoplasm, or both in IHC?
TNFRSF10B is annotated as a membrane protein with an extracellular region at residues 56–210 and a cytoplasmic region at 232–440 (UniProt O14763 topology). The tissue IHC profile describes ubiquitous cytoplasmic expression, with approved reliability and medium agreement between staining and RNA data (HPA tissue IHC). Score membrane-associated and cytoplasmic DAB patterns separately in intact cells, using the same compartment definitions across specimens (standard IHC practice). Cytoplasmic staining alone should therefore be reported as an observed pattern, without treating it as proof of surface receptor abundance (HPA tissue IHC; UniProt O14763 topology). Compare patterns with omission-of-primary controls and tissue morphology before calling diffuse signal specific (standard IHC practice).
How could epitope position change the meaning of TNFRSF10B staining?
The record lists 3 isoforms, Long, 3, and Short, but the selected antibody caption does not identify its epitope (UniProt O14763; datasheet A00410). TNFRSF10B has an extracellular segment at residues 56–210, a membrane segment at 211–231, and a cytoplasmic segment at 232–440 (UniProt O14763 topology). Request an epitope map before claiming that this stain detects every isoform or specifically measures receptor at the cell surface (standard IHC practice). When comparing antibodies, document each epitope and score the same compartments on matched sections (standard IHC practice). Disagreement between stains can prompt epitope or processing checks; it does not by itself establish isoform expression (standard IHC practice).
How should I plan TNFRSF10B immunofluorescence alongside this chromogenic IHC assay?
Use the separate IF/ICC guide to establish fluorescence conditions; the selected antibody evidence here documents paraffin-section chromogenic IHC, not IF performance (datasheet A00410). For multiplexing, pair TNFRSF10B with a marker that identifies the cell population being assessed, such as a validated marker for glandular cells when examining glandular staining (HPA tissue IHC; standard IF practice). Choose a fluorophore channel after checking tissue autofluorescence and spectral overlap on appropriate controls (standard IF practice). If the antibody binds an extracellular epitope, compare staining without permeabilisation; access to a cytoplasmic epitope generally requires permeabilisation (UniProt O14763 topology; standard IF practice). Because this antibody’s epitope is unspecified, confirm that choice experimentally (datasheet A00410).
What should I check when DAB staining spreads beyond expected cells?
The selected protocol used 10% goat serum blocking, a biotinylated secondary antibody, an avidin–biotin detection complex, and DAB (datasheet A00410). Check an omission-of-primary section for secondary, detection-system, and tissue-derived signal before increasing the primary antibody concentration (standard IHC practice). Apply a peroxidase block for chromogenic detection and assess endogenous biotin when using the documented avidin–biotin system; these are general workflow checks (standard IHC practice; datasheet A00410). Compare the documented 1 μg/ml primary condition with a lower concentration on adjacent sections if background persists (datasheet A00410; standard IHC practice). Evaluate background away from tissue edges and damaged areas, where staining can mislead (standard IHC practice).
How can I quantify TNFRSF10B IHC across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because the receptor is membrane annotated while tissue IHC also reports cytoplasmic staining (UniProt O14763 topology; HPA tissue IHC). For an H-score, record percentages at intensity grades 0–3 and sum percentage times grade, giving a range of 0–300 (standard IHC practice). Alternatively report the percentage of positive cells, or positive-cell density per mm² of viable tissue, with the denominator stated explicitly (standard IHC practice). Keep retrieval, detection, image settings, thresholds, and scoring regions consistent across groups (standard IHC practice). Normalise to the relevant viable cell population or tissue area, and report membrane and cytoplasmic results separately (standard IHC practice).
When does TNFRSF10B staining support a true positive call?
Look for reproducible cell-associated signal in intact tissue, and describe membrane and cytoplasmic staining separately (standard IHC practice; UniProt O14763 topology; HPA tissue IHC). The HPA profile reports high staining in several cell populations, including adipocytes and glandular cells, but its tissue IHC reliability is approved with medium RNA agreement (HPA tissue IHC). Exclude tissue-edge staining, necrotic regions, and signal present in an omission-of-primary control before assigning DAB to TNFRSF10B (standard IHC practice). Check endogenous peroxidase and, with the documented avidin–biotin method, detection-system background (standard IHC practice; datasheet A00410). A positive cytoplasmic stain alone does not establish cell-surface receptor localisation or signalling activity (UniProt O14763 topology; HPA tissue IHC).
Boster reagents
Best TNFRSF10B / Tumor necrosis factor receptor superfamily member 10B IHC Antibodies
Anti-TNFRSF10B antibodies have paraffin-section IHC images from human, mouse and rat samples (catalog IHC captions); A00410-2 also has IF images from all three species (catalog IF captions).
Real IHC data
Anti-DR5/TNFRSF10B Antibody ®
Cat # A00410
Real IHC data
Anti-DR5 TNFRSF10B Antibody
Cat # A00410-2
Real IHC data
Anti-DR5/TNFRSF10B Antibody ®
Cat # A00410-5
Real IHC data
Anti-DR5/TNFRSF10B Antibody ®
Cat # PA1842
A00410 shows paraffin-section IHC in rat kidney, mouse intestine and human intestinal cancer (A00410 IHC captions); A00410-2 shows formaldehyde-fixed mouse kidney IHC (A00410-2 IHC caption). A00410-5 shows paraffin-section IHC in human endometrioid adenocarcinoma, lung cancer and tonsil (A00410-5 IHC captions); PA1842 shows human lung cancer IHC(P) (PA1842 IHC caption).
Which to pick: For human tissue IHC, choose A00410-5 when its paraffin-section example using EDTA at pH 8.0 and 2 μg/ml fits your assay; PA1842 has a human lung cancer IHC(P) image and a listed range of 0.5–1 μg/ml (A00410-5 IHC caption; PA1842 IHC caption and catalog dilution). For IF/ICC, choose A00410-2: its IF images include human HepG2 cells and human, mouse and rat samples, with 5–10 μg/mL listed for IF (A00410-2 IF captions and catalog dilution). For cross-species paraffin IHC, A00410 has human, mouse and rat image examples; fixation is unreported for A00410, A00410-5 and PA1842, while A00410-2’s mouse kidney example specifies fixation (catalog IHC captions). The selected A00410 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image A00410).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O14763 (TR10B_HUMAN, Tumor necrosis factor receptor superfamily member 10B).
- Human Protein Atlas. TNFRSF10B tissue IHC expression (reliability: Approved).
- Human Protein Atlas. TNFRSF10B subcellular location (ICC-IF): Membrane.
- Human Protein Atlas. TNFRSF10B antibody validation summary (1 antibodies).
- TNFRSF10B Implicated in Osteoarthritis Protection via the Alpha-Tocopherol-to-Sulfate Ratio: A Multiomics and Mendelian Randomization Study. International Journal of Molecular Sciences 2026 — PMC13607894.
- THE CRITICAL ROLE OF THE HISTONE MODIFICATION ENZYME SETDB2 IN THE PATHOGENESIS OF ACUTE RESPIRATORY DISTRESS SYNDROME. Shock (Augusta, Ga.) 2023 — PMC10417228.
- System-wide identification of novel de-ubiquitination targets for USP10 in gastric cancer metastasis through multi-omics screening. BMC cancer 2024 — PMC11209979.
- Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease. Cell death & disease 2021 — PMC8492692.
- PubMed PMID:9285725 — UniProt-cited evidence.
- PubMed PMID:9311998 — UniProt-cited evidence.
- PubMed PMID:9373179 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TNFRSF10B (Tumor necrosis factor receptor superfamily member 10B). Expected localisation Cytoplasm observed (HPA tissue IHC); membrane topology (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A00410). Validated IHC antibody: A00410 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded rat kidney tissue; fixative not specified (datasheet A00410); 2. Fixation: Image fixative and duration unreported (datasheet A00410); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A00410); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00410); 8. Primary antibody: Rabbit anti-TNFRSF10B, 0.5-1μg/ml (datasheet A00410); 9. Primary incubation: Overnight at 4 °C (datasheet A00410). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A00410); Caveat: Brain staining varies: Purkinje cells high, glia low (HPA tissue IHC); Isoform / epitope: 3 isoforms; check extracellular vs cytoplasmic epitope coverage (UniProt); Regulation: HCMV UL141 blocks surface expression (UniProt). Evidence: UniProt O14763, HPA tissue IHC · Approved, HPA ICC-IF · Membrane, Datasheet A00410, PMC13607894, PMC10417228. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TNFRSF10B/immunohistochemistry-ihc-guide.